- Home
- ANAB vs OCUL Comparison
ANAB vs OCUL Comparison
Compare ANAB & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANAB | OCUL |
|---|---|---|
| Founded | 2005 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.9B |
| IPO Year | 2015 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ANAB | OCUL |
|---|---|---|
| Price | $50.91 | $9.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 9 |
| Target Price | ★ $71.67 | $23.56 |
| AVG Volume (30 Days) | 469.9K | ★ 1.9M |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $234,603,000.00 | $1,990,000.00 |
| Revenue This Year | N/A | $7.93 |
| Revenue Next Year | $52.14 | $96.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 157.01 | 3.48 |
| 52 Week Low | $23.15 | $6.23 |
| 52 Week High | $73.30 | $16.44 |
Technical Indicators
Market Signals| Indicator | ANAB | OCUL |
|---|---|---|
| Relative Strength Index (RSI) | 34.85 | 41.60 |
| Support Level | $50.09 | $9.24 |
| Resistance Level | $51.67 | $9.93 |
| Average True Range (ATR) | 2.45 | 0.56 |
| MACD | -0.41 | -0.14 |
| Stochastic Oscillator | 16.64 | 0.00 |
Price Performance
Historical ComparisonAbout ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.